Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

Company Overview

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets.

Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.

Key Stats

• Today's Range: $30.10 to $32.31
• 50-Day Range: $16.70 to $27.12
• 52-Week Range: $13.09 to $32.31
• Volume: 567,626 shs
• Average Volume: 345,858 shs
• Market Capitalization: $829.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.33
• Consensus Rating: Hold

Eton Pharmaceuticals Stock Analysis - MarketRank™

Eton Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 122nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Eton Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Eton Pharmaceuticals has a consensus price target of $39.33, representing about 29.7% upside from its current price of $30.33.

Amount of Analyst Coverage

Eton Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 121.95%

Earnings Growth

Earnings for Eton Pharmaceuticals are expected to grow by 121.95% in the coming year, from $0.82 to $1.82 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eton Pharmaceuticals is -168.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eton Pharmaceuticals is -168.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eton Pharmaceuticals has a P/B Ratio of 30.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.83% of the float of Eton Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eton Pharmaceuticals has a short interest ratio ("days to cover") of 4.24.

Change versus previous month

Short interest in Eton Pharmaceuticals has recently decreased by 5.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eton Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eton Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.55

News Sentiment

Eton Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Eton Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

6 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.03% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.86% of the stock of Eton Pharmaceuticals is held by institutions.

ETON Stock Analysis - Frequently Asked Questions

How have ETON shares performed this year?

Eton Pharmaceuticals' stock was trading at $16.91 at the start of the year. Since then, ETON stock has increased by 79.4% and is now trading at $30.33.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) issued its quarterly earnings data on Thursday, March, 19th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by $0.07. The company earned $21.28 million during the quarter, compared to analysts' expectations of $20.58 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 2.60% and a negative net margin of 5.75%.
Read the conference call transcript.

When did Eton Pharmaceuticals IPO?

Eton Pharmaceuticals (ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

Who are Eton Pharmaceuticals' major shareholders?

Top institutional investors of Eton Pharmaceuticals include Bank of New York Mellon Corp (0.41%) and Granite Investment Partners LLC (0.03%). Insiders that own company stock include Opaleye Management Inc, David Krempa and James R Gruber.
View institutional ownership trends.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 3/19/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ETON
• CIK: 1710340
• Web: www.etonpharma.com
• Phone: (847) 787-7361
• Fax: N/A
• Employees: 20
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Eton Pharmaceuticals: $39.33
• High Price Target: $52.00
• Low Price Target: $31.00
• Potential Upside/Downside: +29.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 36.99
• P/E Growth: N/A
• Net Income: -$4.60 million
• Net Margins: -5.75%
• Pretax Margin: -5.70%
• Return on Equity: -2.60%
• Return on Assets: -0.66%

Debt

• Debt-to-Equity Ratio: 0.83
• Current Ratio: 1.57
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $79.95 million
• Price / Sales: 10.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.98 per share
• Price / Book: 30.95

Miscellaneous

• Outstanding Shares: 27,360,000
• Free Float: 22,848,000
• Market Cap: $829.83 million
• Optionable: Optionable
• Beta: 0.82